Skip to main content

John F. Sylvia

Mintz Achieves Full First Circuit Victory on Behalf of Keryx Biopharmaceuticals Case Study
Mintz litigators achieved a complete victory on behalf of our client Keryx Biopharmaceuticals in a putative securities class action case seeking over $100 million in damages.
BREAKING DOWN THE SPAC SURGE: A Review of Key Trends & Issues Defining the Phenomenon Case Study
Mintz analyzed PitchBook data to produce an in-depth report on the record rise in special purpose acquisition company (SPAC) fundraising in the US since 2020 and the recent increase in SPAC merger activity. We also explore how SPACs could evolve and litigation challenges to SPAC IPOs and transactions.
Former State Street Exec Cleared of SEC Fraud Claims Case Study
Mintz’s victory in a trial before the SEC’s Chief Administrative Law Judge cleared a former State Street executive of charges related to the Dodd-Frank Wall Street Reform and Consumer Protection Act. After the SEC overturned the decision, the First Circuit’s reversal of the Commission made new law.
Mintz Achieves Victory for Vertex in First Circuit Case Study
Mintz secured two MA federal court wins and one at the First Circuit for Vertex Pharmaceuticals, Inc. and several senior executives in a securities case about clinical trial result disclosures. The decision clarified the First Circuit standard for pleading scienter in securities fraud cases.